{
  "id": "5aef080812863324",
  "title": "STAT+: Pharmalittle: We\u2019re reading about a \u2018sledgehammer\u2019 to innovation, longevity medicine, and more",
  "description": "Noubar Afeyan, one of biotech\u2019s top investors, warned\u00a0that a backlash against science in the U.S. could take \u201ca sledgehammer\u201d to biotech innovation",
  "content": "Noubar Afeyan, one of biotech\u2019s top investors, warned\u00a0that a backlash against science in the U.S. could take \u201ca sledgehammer\u201d to biotech innovation",
  "source": "STAT",
  "source_url": "https://www.statnews.com/pharmalot/2026/01/12/pharma-biotech-weight-obesity-amazon-stoke-novo-abivax/?utm_campaign=rss",
  "published_at": "2026-01-12T14:04:32+00:00",
  "fetched_at": "2026-01-13T00:20:01.657666+00:00",
  "category": "health_biotech",
  "subcategory": null,
  "keywords": [
    "ai",
    "longevity"
  ],
  "location": null,
  "raw_data": {
    "title": "STAT+: Pharmalittle: We\u2019re reading about a \u2018sledgehammer\u2019 to innovation, longevity medicine, and more",
    "description": "Noubar Afeyan, one of biotech\u2019s top investors, warned\u00a0that a backlash against science in the U.S. could take \u201ca sledgehammer\u201d to biotech innovation",
    "url": "https://www.statnews.com/pharmalot/2026/01/12/pharma-biotech-weight-obesity-amazon-stoke-novo-abivax/?utm_campaign=rss",
    "published": "2026-01-12T14:04:32+00:00",
    "source": "STAT"
  }
}